The 14 biopharmaceutical companies that have gone public so far this year in the US provided an average return of 18.6% at the end of the first quarter, dropping from an average return of 52.8% just a few weeks ago when only 10 drug developers had launched initial public offerings.
Scrip's last look at IPOs noted that returns from first-time offerings far outpaced broader stock indices as of March 9,...






